This is a summary of the European public assessment report (EPAR) for Luveris. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Luveris.
Therapeutic Indication
### Therapeutic indication Luveris in association with a follicle-stimulating-hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (LH) and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level <1.2 IU/l.
Therapeutic Area (MeSH)
ATC Code
G03GA07
ATC Item
lutropin alfa
Pharmacotherapeutic Group
Sex hormones and modulators of the genital system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| lutropin alfa | N/A | 重组人促黄体激素α |
EMA Name
Luveris
Medicine Name
Luveris
Aliases
N/ANo risk management plan link.
